Publication details

Prognostic Importance of Cell Cycle Regulators Cyclin D1 (CCND1) and Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B/p27) in Sporadic Gastric Cancers

Authors	MINARIKOVA Petra BENESOVA Lucie HALKOVA Tereza BELSANOVA Barbora TUCKOVA Inna BELINA Frantisek DUŠEK Ladislav ZAVORAL Miroslav MINARIK Marek
Year of publication	2016
Type	Article in Periodical
Magazine / Source	Gastroenterology Research and Practice
MU Faculty or unit	Faculty of Medicine
Citation
Doi	http://dx.doi.org/10.1155/2016/9408190
Field	Other specializations of internal medicine
Keywords	HELICOBACTER-PYLORI INFECTION; IN-SITU HYBRIDIZATION; PROBE AMPLIFICATION; THERAPEUTIC TARGET; GENE AMPLIFICATION; CYTOPLASMIC P27; BREAST-CANCER; DIFFUSE-TYPE; HER2 STATUS; CARCINOMA
Description	Background. Gastric cancer is known for a notable variety in the course of the disease. Clinical factors, such as tumor stage, grade, and localization, are key in patient survival. It is expected that molecular factors such as somatic mutations and gene amplifications are also underlying tumor biological behavior and may serve as factors for prognosis estimation. Aim. The purpose of this study was to examine gene amplifications from a panel of genes to uncover potential prognostic marker candidates. Methods. A panel of gene amplifications including 71 genes was tested by multiplex ligation-dependent probe amplification (MLPA) technique in 76 gastric cancer samples from a Caucasian population. The correlation of gene amplification status with patient survival was determined by the Kaplan-Meier method. Results. The amplification of two cell cycle regulators, CCND1 and CDKN1B, was identified to have a negative prognostic role. The medial survival of patients with gastric cancer displaying amplification compared to patients without amplification was 192 versus 725 days for CCND1 (P = 0.0012) and 165 versus 611 days for CDKN1B (P = 0.0098). Conclusion. Gene amplifications of CCND1 and CDKN1B are potential candidates to serve as prognostic markers for the stratification of patients based on the estimate of survival in the management of gastric cancer patients.